Compugen (CGEN)
(Delayed Data from NSDQ)
$1.76 USD
-0.07 (-3.83%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.73 -0.03 (-1.70%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
Compugen Ltd. [CGEN]
Reports for Purchase
Showing records 1 - 20 ( 60 total )
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
2Q22: Strategic Priorities Identified. Cash Runway Extended
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Anti-TIGIT Competitors: A Case for Therapies From Compugen
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Highlights from the AACR Meeting Part II: CGEN & TCRR
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
AACR 2022 Abstract Titles Released (Part II): CGEN, GNTA, MRUS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Compugen Ltd.
Industry: Medical - Biomedical and Genetics
Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: Research Department